Genovate Biotechnology Co Ltd Cash Flow Conversion Efficiency
Genovate Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has a cash flow conversion efficiency ratio of 0.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$16.93 Million ≈ $533.39K USD) by net assets (NT$1.38 Billion ≈ $43.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genovate Biotechnology Co Ltd (2015–2025)
Cash flow conversion efficiency of Genovate Biotechnology Co Ltd from 2015 to 2025. This chart illustrates how Genovate Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genovate Biotechnology Co Ltd share price for real-time trading data and today's change.
Genovate Biotechnology Co Ltd Cash Flow Conversion Ratio Explained
Genovate Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genovate Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Genovate Biotechnology Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MFS High Income Municipal Closed Fund
NYSE:CXE
|
0.024x |
|
Air Busan Co Ltd
KO:298690
|
0.154x |
|
LDR Turizm AS
IS:LIDER
|
0.160x |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
0.119x |
|
Kamdhenu Limited
NSE:KAMDHENU
|
0.035x |
|
Optiscan Imaging Ltd
AU:OIL
|
-0.188x |
|
Digimarc Corporation
NASDAQ:DMRC
|
-0.027x |
|
KUB Malaysia Bhd
KLSE:6874
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Genovate Biotechnology Co Ltd from 2015 to 2025. Review cash generation quality of Genovate Biotechnology Co Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.38 Billion ≈ $43.49 Million |
NT$43.79 Million ≈ $1.38 Million |
0.032x | -16.58% |
| 2024-12-31 | NT$1.45 Billion ≈ $45.66 Million |
NT$55.11 Million ≈ $1.74 Million |
0.038x | -34.11% |
| 2023-12-31 | NT$1.47 Billion ≈ $46.27 Million |
NT$84.78 Million ≈ $2.67 Million |
0.058x | +5293.20% |
| 2022-12-31 | NT$1.41 Billion ≈ $44.45 Million |
NT$1.51 Million ≈ $47.57K |
0.001x | +108.55% |
| 2021-12-31 | NT$1.38 Billion ≈ $43.44 Million |
NT$-17.26 Million ≈ $-543.75K |
-0.013x | -120.50% |
| 2020-12-31 | NT$1.43 Billion ≈ $44.93 Million |
NT$87.08 Million ≈ $2.74 Million |
0.061x | +93.55% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.37 Million |
NT$44.43 Million ≈ $1.40 Million |
0.032x | -21.55% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.26 Million |
NT$62.88 Million ≈ $1.98 Million |
0.040x | +105.73% |
| 2017-12-31 | NT$1.60 Billion ≈ $50.40 Million |
NT$31.27 Million ≈ $985.27K |
0.020x | -37.70% |
| 2016-12-31 | NT$2.25 Billion ≈ $70.86 Million |
NT$70.58 Million ≈ $2.22 Million |
0.031x | +104.92% |
| 2015-12-31 | NT$2.12 Billion ≈ $66.93 Million |
NT$32.53 Million ≈ $1.02 Million |
0.015x | -- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more